微小RNA miR-21和miR-31在口腔鳞癌组织中的表达及意义

目的:检测口腔鳞癌中微小RNA miR-21和miR-31的表达,探讨其与肿瘤发展的关系。方法:应用实时荧光定量PCR的方法检测72例口腔鳞癌,38例正常口腔粘膜miR-21和miR-31的表达,统计学分析其表达与肿瘤临床分期和病理分型的关系。结果:①口腔鳞癌组织与对照组比较,微小RNA miR-21和miR-31的表达都有显著增高(P0.05),其中miR-21的增高更为显著(P0.001)。②统计学分析表明,miR-21的表达在晚期鳞癌组织较早中期鳞癌组织增高更为显著(P0.01),在低分化鳞癌组织较中、高分化鳞癌组织增高更为显著(p0.001);MiR-31的表达水平在不同肿瘤临床分期和病理分型鳞癌组织中无明显差异(P0.05)。结论:miR-21和miR-31在口腔鳞癌发生发展过程中表达有明显增高,其中miR-21表达水平可作为潜在的口腔鳞癌临床分期分级和预后的指标。     

微小RNAmiR-21和miR-31在13腔鳞癌组织中的表达及意义

目的：检测口腔鳞癌中微小RNA miR-21和miR-31的表达,探讨其与肿瘤发展的关系。方法：应用实时荧光定量PCR的方法检测72例口腔鳞癌,38例正常口腔粘膜miR-21和miR-31的表达,统计学分析其表达与肿瘤临床分期和病理分型的关系。结果：①口腔鳞癌组织与对照组比较,微小RNA miR-21和miR-31的表达都有显著增高（P〈0.05）,其中miR-21的增高更为显著（P〈0.001）。②统计学分析表明,miR-21的表达在晚期鳞癌组织较早中期鳞癌组织增高更为显著（P〈0.01）,在低分化鳞癌组织较中、高分化鳞癌组织增高更为显著（p〈0.001）;MiR-31的表达水平在不同肿瘤临床分期和病理分型鳞癌组织中无明显差异（P〉0.05）。结论：miR-21和miR-31在口腔鳞癌发生发展过程中表达有明显增高,其中miR-21表达水平可作为潜在的口腔鳞癌临床分期分级和预后的指标。     

黑色素瘤患者血浆miR-21表达与临床病理特征的相关性

摘要 目的：探讨黑色素瘤患者血浆miR-21表达与临床病理特征的相关性。方法：2018年2月到2019年5月选择在本院诊治的黑色素瘤患者121作为黑色素瘤组,另选取同期良性皮肤肿瘤患者121例作为良性组。采集患者的空腹静脉血并提取血浆,采用qRT-PCR 技术检测血浆miR-21表达。调查患者的临床病理特征并进行相关性分析。结果：黑色素瘤组的血浆miR-21相对表达水平显著高于良性组(P<0.05)。在黑色素瘤组中,血浆miR-21相对表达水平与患者的年龄、性别、饮酒、肿瘤部位等无相关性(P>0.05),与临床分期、肿瘤转移、溃疡、吸烟等有显著相关性(P<0.05)。取miR-21诊断黑色素瘤的临界值(4.71),其诊断黑色素瘤的敏感性、特异性、准确性分别为77.6 %、87.0 %和81.7 %。logistic 回归模型分析显示吸烟、溃疡、miR-21表达水平都为影响黑色素瘤发生的重要因素(P<0.05)。结论：miR-21变化在黑色素瘤中呈现高表达,且与临床特征显著相关性,早期鉴别诊断黑色素瘤的预后效果比较好,同时有助于提高患者的生存率与生活质量。     

miR-145与肿瘤相关研究及其临床应用

microRNAs(miRs)是一类长约22核苷酸的内源性非编码单链RNA分子,对生长发育、细胞增殖、凋亡乃至肿瘤发生发展等生命过程具有重要作用.其中,miR-145是研究最多的miRs之一,研究发现其在多种肿瘤组织中表达下调.通过与多种靶分子,如OCT4、MUC1等相互作用,miR-145可影响肿瘤细胞的增殖、转移及凋亡等过程.在临床应用方面,多项研究发现,miR-145表达水平与肿瘤患者的诊断及预后具有良好的相关性.此外,其表达水平还与卵巢癌等多种肿瘤的化疗耐药性相关.本文就miR-145对肿瘤的发生发展的作用及影响,以及在临床上诊断、治疗和预后等方面的应用前景做一综述.     

miR-133b与miR-155在非小细胞肺癌患者肿瘤及周围组织中的表达及意义

探讨miR-133b与miR-155在非小细胞肺癌患者肿瘤及周围组织中的表达及意义。选择在湖北科技学院附属第一医院接受治疗的47例非小细胞肺癌患者作为研究对象,收集其肺癌组织和周围正常组织标本,采用Real-time PCR检测miR-133b和miR-155在肿瘤及周围组织中的表达情况,分析其与患者临床和病理特征之间的相关性。结果显示,肿瘤组织中miR-133b相对表达量为221.4±1.013,周围正常组织为605.8±1.001,两者比较差异显著(p0.05);肿瘤组织中miR-155相对表达量为643.2±1.118,周围组织为386.9±1.097,两者比较差异显著(p0.05)。即Real-time PCR检测患者肿瘤组织中的miR-133表达明显低于周围正常组织,miR-155的表达明显高于周围正常组织;miR-133b和miR-155的表达与患者年龄、性别、病理类型无明显相关性;而与临床分期和淋巴结转移情况明显相关(p0.05),其中miR-133b表达水平与淋巴结转移呈明显负相关,miR-155表达水平与淋巴结转移呈明显正相关;miR-133b的表达还与肿瘤分化程度明显相关(p0.05)。综上所述,miR-133b和miR-155的异常表达与非小细胞肺癌的发生和发展密切相关,对二者表达水平进行检测有助于及早发现、筛选和诊断非小细胞癌患者,对患者预后评估具有一定临床价值。     

食道癌组织miR-21、miR-182表达与临床病理特征及预后的关系

目的:探讨食道癌组织微小RNA-21(miR-21)、微小RNA-182(miR-182)表达与临床病理特征及预后的关系。方法:选取2011年4月到2013年7月期间在我院接受手术治疗的食道癌患者84例,取患者的癌组织和癌旁正常组织作为检验标本,比较癌组织和癌旁正常组织中miR-21、mi R-182的表达水平,并分析食道癌组织中mi R-182、mi R-21的表达与临床病理特征及预后的关系。结果:癌组织中mi R-21、mi R-182的相对表达量明显高于癌旁正常组织,差异有统计学意义(P<0.05)。食道癌组织中mi R-21的表达与淋巴结转移、临床分期有关(P<0.05),与性别、年龄、分化程度、肿瘤大小无关(P>0.05);食道癌患者癌组织中miR-182的表达与年龄、性别、肿瘤大小无关(P>0.05),与分化程度、临床分期、淋巴结转移有关(P<0.05)。食道癌癌组织中miR-21、miR-182高表达患者的中位生存时间均低于低表达患者,差异有统计学意义(P<0.05)。结论:食道癌组织mi R-21、mi R-182表达与患者的部分临床病理特征及预后有关,两者有望成为食道癌新的治疗靶点。     

血浆microRNA在早期乳腺癌诊断中的价值

目的：探讨不同microRNA的表达及评估血浆microRNA作为早期乳腺癌诊断的新标志物的价值。方法：我们收集了49例早期乳腺癌的术前血浆作为实验样本和36例健康女性血浆作为对照样本。应用反转录和实时荧光定量聚合酶链反应,我们检测miR-21,miR-205,miR-222这三个候选基因的相对表达量并分析了这三个候选microRNA表达与临床病理特征的关系。结果：我们发现,与健康对照相比,miR-21（1．565,P=0．022）andmiR-222（2．258,P〈0．001）在乳腺癌病人血浆中的表达明显升高,而miR-205（0．591,P=0．001）在乳腺癌病人血浆中的表达明显下降。并且在临床病例资料数据的比较中,miR-21（P=0．0101）在乳腺癌病人中的表达水平与雌激素受体和孕激素受体相关。血浆中miR-222的表达水平在肿瘤不同分期中明显不同。结论：本实验证明miR一21,miR-205andmiR．222的表达水平与乳腺癌的病理特征明显相关,可以作为乳腺癌的潜在标志物。     

RBM10通过影响miR-21稳定性参与调控人乳腺癌细胞增殖及转移活性

目的:分析miR-21和RNA结合基序(RBM)在人乳腺癌组织及相应肿瘤细胞中的表达相关性和功能联系。方法:通过Oncomine或starBase数据库分析miR-21和RBM10表达数据,揭示其在人乳腺癌和对照组织中的表达差异;采用人乳腺癌细胞MCF-7、MDA-MB-231和永生化的人乳腺正常上皮细胞MCF-10A进一步分析miR-21和RBM10在乳腺癌细胞和正常乳腺细胞中的表达差异;采用CCK-8法检测敲低RBM10对MCF-7细胞增殖的影响;采用Transwell实验检测敲低RBM10对MCF-7细胞侵袭与迁移能力的调控差异;用放线菌素D处理MCF-7细胞,检测不同时间点miR-21的相对含量反映其稳定性。结果:生物信息学分析结果显示miR-21和RBM10在乳腺癌组织中显著高表达;与组织表达结果类似,在乳腺癌细胞中miR-21和RBM10的表达量显著高于正常乳腺细胞;miR-21与RBM10的表达呈正相关;敲低RBM10抑制MCF-7细胞的增殖、迁移与侵袭,而同时过表达miR-21会减弱这种抑制效应;敲低RBM10能够显著降低miR-21的稳定性。结论:RBM10通过影响miR-21的稳定性参与调控人乳腺癌细胞功能活性。RBM10在肿瘤中的作用仍有待进一步研究,不能简单地概括为一种抑癌因子或致癌因子。     

食管癌组织miR-21、miR-182表达与临床病理特征及预后的关系

目的:探讨食管癌组织微小RNA-21(miR-21)、微小RNA-182(miR-182)表达与临床病理特征及预后的关系。方法:选择2010年10月至2014年2月期间在我院治疗的120例食管癌患者为研究对象,采集患者的食管癌组织及癌旁组织,采用荧光定量PCR检测组织中miR-21、miR-182表达量,采用Kaplan-Meier法分析患者生存情况。结果:与癌旁组织相比,食管癌组织中miR-21、miR-182表达量明显升高(P<0.05)。食管癌组织中miR-21、miR-182表达均与TNM分期和淋巴结转移相关(P<0.05)。miR-21低表达患者的5年生存率明显高于高表达患者(P<0.05),miR-182低表达患者的5年生存率明显高于高表达患者(P<0.05)。结论:miR-21、miR-182表达量在食管癌中上调,与食管癌TNM分期和淋巴结转移相关。miR-21高表达以及miR-182高表达患者5年生存率下降,检测miR-21、miR-182表达量在食管癌患者预后预测中具有一定临床意义。     

MicroRNA-21可促进金华猪胚胎肝脏生长

microRNAs是一种小分子非编码RNA,广泛参与细胞的生长发育、分化和凋亡等生物学过程. microRNA-21(miR-21)是一个在实体肿瘤中高表达的miRNA,可促进癌细胞增殖. 为了研究miR-21在金华猪生长过程中的作用,本试验选取了金华猪80日龄胚胎的心、肝、脾、肺、肾、小肠、胰脏、皮脂组织,进行miR-21组织表达谱研究,结果发现miR-21在肝脏中的表达最高. 进一步以肝脏为对象,研究miR-21在金华猪不同生长阶段中的表达,结果显示胚胎80日龄的miR-21表达量最高（P<0.01）,其次是胚胎期的60日龄和105日龄,出生后1至120日龄miR-21的表达量均维持在较低的水平且相互之间差异不显著(P>0.05). 利用KEGG软件对miR-21预测的靶基因进行通路归类分析表明miR-21参与细胞代谢、生长等过程,从中选择两个抑制细胞增殖的靶基因,增强子结合蛋白（CCAAT/enhancer binding protein,Cebpa) 和原肌球蛋白1基因（tropomyosin 1,Tpm1),qRT-PCR检测二者在不同生长阶段的mRNA表达量,结果其表达趋势与miR-21相反,其中胚胎期80天表达量最低(P<0.05). 综上表明miR-21可能具有促进胚胎肝脏生长的作用.     

Interplay between HIV-1 infection and host microRNAs

Using microRNA array analyses of in vitro HIV-1-infected CD4(+) cells, we find that several host microRNAs are significantly up- or downregulated around the time HIV-1 infection peaks in vitro. While microRNA-223 levels were significantly enriched in HIV-1-infected CD4(+)CD8(-) PBMCs, microRNA-29a/b, microRNA-155 and microRNA-21 levels were significantly reduced. Based on the potential for microRNA binding sites in a conserved sequence of the Nef-3'-LTR, several host microRNAs potentially could affect HIV-1 gene expression. Among those microRNAs, the microRNA-29 family has seed complementarity in the HIV-1 3'-UTR, but the potential suppressive effect of microRNA-29 on HIV-1 is severely blocked by the secondary structure of the target region. Our data support a possible regulatory circuit at the peak of HIV-1 replication which involves downregulation of microRNA-29, expression of Nef, the apoptosis of host CD4 cells and upregulation of microRNA-223.     

MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells

MicroRNAs are involved in cancer-related processes. The microRNA-21(miR-21) has been identified as the only miRNA over-expressed in a wide variety of cancers, including cervical cancer. However, the function of miR-21 is unknown in cervical carcinomas. In this study, we found that the inhibition of miR-21 in HeLa cervical cancer cells caused profound suppression of cell proliferation, and up-regulated the expression of the tumor suppressor gene PDCD4. We also provide direct evidence that PDCD4-3′UTR is a functional target of miR-21 and that the 18 bp putative target site can function as the sole regulatory element in HeLa cells. These results suggest that miR-21 may play an oncogenic role in the cellular processes of cervical cancer and may serve as a target for effective therapies.     

microRNA-215异常激活抑制Dicer1促进肝癌细胞迁移和转化

microRNA异常表达促进癌症的发生发展.本研究通过microRNA表达谱分析2个肝癌细胞和2个正常细胞microRNA的表达,寻找与肝癌相关的microRNA,发现microRNA-215在肝癌细胞中高表达,q RT-PCR验证microRNA-215在肝癌细胞呈显著高表达.进一步研究发现,microRNA-215直接靶向Dicer1基因的3′UTR并抑制Dicer1蛋白表达,Dicer1是microRNA加工成熟过程中必需的蛋白.过表达microRNA-215抑制Dicer1从而促进肝癌细胞迁移和转化,而抑制microRNA-215表达起相反作用.Dicer1抑制后,许多抑癌microRNA表达被抑制,从而促进迁移和转化.相对于癌旁组织,Dicer1在肝癌组织呈明显低表达.本研究揭示,microRNA-215异常活化并抑制Dicer1表达与肝癌发展相关.     

Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells

Background

Hepatitis C virus (HCV) has been reported to regulate cellular microRNAs. The HCV core protein is considered to be a potential oncoprotein in HCV-related hepatocellular carcinoma, but HCV core-modulated cellular microRNAs are unknown. The HCV core protein regulates p21^Waf1/Cip1 expression. However, the mechanism of HCV core-associated p21^Waf1/Cip1 regulation remains to be further clarified. Therefore, we attempted to determine whether HCV core-modulated cellular microRNAs play an important role in regulating p21^Waf1/Cip1 expression in human hepatoma cells.

Methods

Cellular microRNA profiling was investigated in core-overexpressing hepatoma cells using TaqMan low density array. Array data were further confirmed by TaqMan real-time qPCR for single microRNA in core-overexpressing and full-length HCV replicon-expressing cells. The target gene of microRNA was examined by reporter assay. The gene expression was determined by real-time qPCR and Western blotting. Apoptosis was examined by annexin V-FITC apoptosis assay. Cell cycle analysis was performed by propidium iodide staining. Cell proliferation was analyzed by MTT assay.

Results

HCV core protein up- or down-regulated some cellular microRNAs in Huh7 cells. HCV core-induced microRNA-345 suppressed p21^Waf1/Cip1 gene expression through targeting its 3′ untranslated region in human hepatoma cells. Moreover, the core protein inhibited curcumin-induced apoptosis through p21^Waf1/Cip1-targeting microRNA-345 in Huh7 cells.

Conclusion and Significance

HCV core protein enhances the expression of microRNA-345 which then down-regulates p21^Waf1/Cip1 expression. It is the first time that HCV core protein has ever been shown to suppress p21^Waf1/Cip1 gene expression through miR-345 targeting.     

上皮性卵巢癌患者血清 microRNA-21 的水平及其临床意义研究

目的:检测上皮性卵巢癌患者血清中microRNA-21的表达,并探讨其作为标记物预测上皮性卵巢癌化疗耐药患者预后的可行性。方法:采用探针型实时荧光定量逆转录聚合酶链反应检测和比较20例上皮性卵巢癌患者和10例正常人卵巢血清标本中microRNA-21的表达,并分析血清microRNA-21水平与上皮性卵巢癌患者化疗耐药及其临床病理特征的相关性。结果:正常人、上皮性卵巢癌化疗敏感和化疗耐药患者血清中micro RNA-21的相对表达量分别为0.573±0.318、2.606±1.057、26.766±26.710,上皮性卵巢癌化疗敏感和化疗耐药患者血清中miR-21的相对表达量均显著高于正常人血清中miR-21的相对表达量(P<0.05),而上皮性卵巢癌化疗耐药患者血清中miR-21表达显著高于上皮性卵巢癌化疗敏感患者,差异有统计学意义(P<0.05)。上皮性卵巢癌化疗耐药患者血清miR-21表达水平与其手术-病理分期无及是否发生淋巴结转移均无明显相关性(P>0.05)。结论:上皮性卵巢癌患者血清microRNA-21水平显著升高,可能作为其化疗耐药的预测参考指标,但血清microRNA-21水平与上皮性卵巢癌化疗耐药患者的不良预后并无显著相关性。     

Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics

Substantial evidence indicates that microRNA-21 (miR-21) is a key oncomiR in carcinogenesis and is significantly elevated in multiple myeloma (MM). In this study, we explored the role of miR-21 in human MM cells and searched for miR-21 targets. By knocking down the expression of endogenous miR-21 in U266 myeloma cells, we observed reduced growth, an arrested cell cycle, and increased apoptosis. To further understand its molecular mechanism in the pathogenesis of MM, we employed a SILAC (stable isotope labeling by amino acids in cell culture)-based quantitative proteomic strategy to systematically identify potential targets of miR-21. In total, we found that the expression of 178 proteins was up-regulated significantly by miR-21 inhibition, implying that they could be potential targets of miR-21. Among these, the protein inhibitor of activated STAT3 (PIAS3) was confirmed as a direct miR-21 target by Western blotting and reporter gene assays. We further demonstrated that miR-21 enhances the STAT3-dependent signal pathway by inhibiting the function of PIAS3 and that down-regulation of PIAS3 contributes to the oncogenic function of miR-21. This elucidation of the role of PIAS3 in the miR-21-STAT3 positive regulatory loop not only may shed light on the molecular basis of the biological effects of miR-21 observed in MM cells but also has direct implications for the development of novel anti-MM therapeutic strategies.     

The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells

Background

The excess and persistent accumulation of fibroblasts due to aberrant tissue repair results in fibrotic diseases such as idiopathic pulmonary fibrosis. Recent reports have revealed significant changes in microRNAs during idiopathic pulmonary fibrosis and evidence in support of a role for microRNAs in myofibroblast differentiation and the epithelial-mesenchymal transition in the context of fibrosis. It has been reported that microRNA-21 is up-regulated in myofibroblasts during fibrosis and promotes transforming growth factor-beta signaling by inhibiting Smad7. However, expression changes in microRNA-21 and the role of microRNA-21 in epithelial-mesenchymal transition during lung fibrosis have not yet been defined.

Methods

Lungs from saline- or bleomycin-treated C57BL/6 J mice and lung specimens from patients with idiopathic pulmonary fibrosis were analyzed. Enzymatic digestions were performed to isolate single lung cells. Lung epithelial cells were isolated by flow cytometric cell sorting. The expression of microRNA-21 was analyzed using both quantitative PCR and in situ hybridization. To induce epithelial-mesenchymal transition in culture, isolated mouse lung alveolar type II cells were cultured on fibronectin-coated chamber slides in the presence of transforming growth factor-β, thus generating conditions that enhance epithelial-mesenchymal transition. To investigate the role of microRNA-21 in epithelial-mesenchymal transition, we transfected cells with a microRNA-21 inhibitor. Total RNA was isolated from the freshly isolated and cultured cells. MicroRNA-21, as well as mRNAs of genes that are markers of alveolar epithelial or mesenchymal cell differentiation, were quantified using quantitative PCR.

Results

The lung epithelial cells isolated from the bleomycin-induced lung fibrosis model system had decreased expression of epithelial marker genes, whereas the expression of mesenchymal marker genes was increased. MicroRNA-21 was significantly upregulated in isolated lung epithelial cells during bleomycin-induced lung fibrosis and human idiopathic pulmonary fibrosis. MicroRNA-21 was also upregulated in the cultured alveolar epithelial cells under the conditions that enhance epithelial-mesenchymal transition. Exogenous administration of a microRNA-21 inhibitor prevented the increased expression of vimentin and alpha-smooth muscle actin in cultured primary mouse alveolar type II cells under culture conditions that induce epithelial-mesenchymal transition.

Conclusions

Our experiments demonstrate that microRNA-21 is increased in lung epithelial cells during lung fibrosis and that it promotes epithelial-mesenchymal transition.     

MicroRNA-543 promotes cell invasion and impedes apoptosis in pituitary adenoma via activating the Wnt/β-catenin pathway by negative regulation of Smad7

Pituitary adenomas (PA) are commonly occurring benign neoplasms. Identification of molecular pathway resulting in pituitary tumorigenesis remains challenges in endocrine oncology. The present study was conducted with aim of investigating the role of microRNA-543 (miR-543) in PA development. Up-regulated miR-543 and downregulated Smad7 were observed in PA tissues. Afterwards, the specific mechanism of miR-543 and Smad7 in PA were determined with the use of ectopic expression, depletion and reporter assay experiments. Smad7 was confirmed as a target gene of miR-543. HP75 cells treated with overexpressed miR-543 exhibited increased cell proliferation, migration and invasion, while decreased cell apoptosis as well as expression of Cleaved caspase-3 and Cleaved caspase-8 were observed. Suppression of miR-543 contributed to an opposite trend to the above findings. Based on the findings, the inhibition of miR-543 was found to play a tumor suppressive role in PA through the down-regulation of Wnt/β-catenin pathway by negatively regulating Smad7.